期刊文献+

三联用药治疗骨质疏松性椎体压缩骨折骨水泥成形术后残余痛的临床效果 被引量:7

下载PDF
导出
摘要 目的观察碳酸钙D_3颗粒、骨化三醇胶丸联合唑来膦酸治疗骨质疏松性椎体压缩骨折骨水泥成形术后残余痛的临床效果。方法选取2014年6月至2016年12月新乡医学院第一附属医院收治的31例骨质疏松性椎体压缩骨折骨水泥成形术后残余痛患者,给予碳酸钙D_3颗粒、骨化三醇胶丸联合唑来膦酸抗骨质疏松治疗。采用疼痛视觉模拟评分量表(VAS)评估治疗前及治疗后1、3、6个月的疼痛程度;采用Oswestry功能障碍指数(ODI)评估生活质量;测量治疗前及治疗后6个月的骨密度(BMD);统计不良反应发生情况。结果治疗后1、3、6个月的VAS评分与治疗前比较,差异有统计学意义(P<0.05);治疗后1、3、6个月的ODI评分与治疗前比较,差异有统计学意义(P<0.05)。治疗后6个月,BMD为(0.81±0.03)g/m^2,高于治疗前的(0.72±0.06)g/m^2,差异有统计学意义(P<0.05)。治疗期间,6例患者出现药物不良反应,4例可耐受,2例因过度敏感给予对症处理;治疗后,所有患者血钙、肝肾功能及心电图均未见明显异常。结论碳酸钙D_3颗粒、骨化三醇胶丸联合唑来膦酸治疗骨质疏松性椎体压缩骨折骨水泥成形术后残余痛效果显著,不良反应少,能有效改善患者骨密度,提高生活质量。
出处 《河南医学研究》 CAS 2019年第6期1054-1056,共3页 Henan Medical Research
  • 相关文献

参考文献4

二级参考文献48

  • 1NIH consensus conference, osteoporosis prevention, diagnosis and therapy[J]. JAMA ,2001,285:785-795.
  • 2Nancolas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone : diferences in interactions with hydroxyapatite [ J ]. B one,2006,38 : 617-627.
  • 3Penning-van Beest FJ, Erkens JA, Olson M, et al. Loss of treatment benefit due to low compliance with bisphosphonate therapy[ J]. Osteoporosis Int ,2008,19 ( 4 ) :511-517.
  • 4Lyles KW, Colon Emetic CS, Magaziner JS, et al. Zoledmnic acid and clinical fractures and mortality after hip fracture [ J]. N Engl J Med, 2007,357 ( 18 ) : 1799-1809.
  • 5Lewiecki EM. Intravenous zoledronic acid for the treatment of osteoporosis [ J ]. Curr Osteoporos Rep, 2008,6 ( 1 ) : 17-23.
  • 6Boonen S,Black DM, Col6n-Emeric CS,et ah Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older[J]. J Am Geriatr Soc,2010,58(2) :292-299.
  • 7Dalle Carbonare L,Bertoldo F, Lo Cascio V. Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post- menopausalosteoporosis: the HORIZON project [ J ]. Reumatismo, 2009,61 ( 1 ) :54-64.
  • 8FDA. FDA Drug Safety Communication: New contraindication and updated warning on kidney impairment for Reelast( zoledronie acid) ~EB/OL]. (2011-09-01) [2011-10-23]. http://www. fda. gov/Drugs.
  • 9Poole KES, Kaptoge S, Reeve J. Yearly zoledronic acid in postmenopausal osteoporosis[ J]. N Engl J Med, 2007,357 ( 7 ) : 711-712.
  • 10Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research[ J]. J Bone Miner Res, 2007,22(10) : 1479-1491.

共引文献2226

同被引文献115

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部